Genmab A/S (OTCMKTS:GNMSF) Sees Strong Trading Volume After Better-Than-Expected Earnings

Genmab A/S (OTCMKTS:GNMSF) saw strong trading volume on Friday following a better than expected earnings announcement. Approximately 1,700 shares changed hands during trading, a decline of 16% from the previous session’s volume of 2,014 shares.The stock last traded at $311.5099 and had previously closed at $290.00.

The company reported $5.42 EPS for the quarter, beating analysts’ consensus estimates of $3.56 by $1.86. Genmab A/S had a return on equity of 15.34% and a net margin of 21.05%.

Genmab A/S Price Performance

The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The company has a 50-day simple moving average of $268.22 and a two-hundred day simple moving average of $279.28. The stock has a market capitalization of $19.18 billion, a price-to-earnings ratio of 23.49 and a beta of 0.77.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.